WO1997033591A1 - Procede de traitement d'affections associees aux cytokines chez les mammiferes - Google Patents
Procede de traitement d'affections associees aux cytokines chez les mammiferes Download PDFInfo
- Publication number
- WO1997033591A1 WO1997033591A1 PCT/DK1997/000108 DK9700108W WO9733591A1 WO 1997033591 A1 WO1997033591 A1 WO 1997033591A1 DK 9700108 W DK9700108 W DK 9700108W WO 9733591 A1 WO9733591 A1 WO 9733591A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- phenyl
- adenosine
- mmol
- deoxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 54
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 22
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 22
- 241000124008 Mammalia Species 0.000 title claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 208000035475 disorder Diseases 0.000 claims abstract description 13
- 206010040070 Septic Shock Diseases 0.000 claims abstract description 8
- 230000036303 septic shock Effects 0.000 claims abstract description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 6
- 206010061218 Inflammation Diseases 0.000 claims abstract description 6
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 6
- 208000006011 Stroke Diseases 0.000 claims abstract description 6
- 206010003246 arthritis Diseases 0.000 claims abstract description 6
- 230000004054 inflammatory process Effects 0.000 claims abstract description 6
- 230000002175 menstrual effect Effects 0.000 claims abstract description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims description 78
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 56
- -1 perhalomethyl Chemical group 0.000 claims description 41
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 206010012601 diabetes mellitus Diseases 0.000 claims description 12
- 150000002367 halogens Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 150000001412 amines Chemical group 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 229910052799 carbon Chemical group 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 125000005997 bromomethyl group Chemical group 0.000 claims description 6
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 6
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 6
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 6
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 5
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 24
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 24
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 186
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 145
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 125
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 109
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 108
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 74
- 229960005305 adenosine Drugs 0.000 description 74
- 239000000203 mixture Substances 0.000 description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 61
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 59
- 229910001868 water Inorganic materials 0.000 description 59
- 239000011541 reaction mixture Substances 0.000 description 54
- 239000006260 foam Substances 0.000 description 53
- 238000003818 flash chromatography Methods 0.000 description 47
- 238000005160 1H NMR spectroscopy Methods 0.000 description 45
- 238000010828 elution Methods 0.000 description 45
- 235000019439 ethyl acetate Nutrition 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 40
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 39
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 38
- 238000005481 NMR spectroscopy Methods 0.000 description 37
- 238000004128 high performance liquid chromatography Methods 0.000 description 37
- 230000014759 maintenance of location Effects 0.000 description 37
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 32
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 238000004440 column chromatography Methods 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 21
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 20
- 239000007787 solid Substances 0.000 description 19
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 229910021529 ammonia Inorganic materials 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 16
- 102000009346 Adenosine receptors Human genes 0.000 description 15
- 108050000203 Adenosine receptors Proteins 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000012264 purified product Substances 0.000 description 13
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 238000005660 chlorination reaction Methods 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000012043 crude product Substances 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 150000003212 purines Chemical class 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 150000003835 adenosine derivatives Chemical class 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- MDEYYSFYGIQFMP-KQYNXXCUSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(methoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NOC)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MDEYYSFYGIQFMP-KQYNXXCUSA-N 0.000 description 6
- UENGBOCGGKLVJJ-UHFFFAOYSA-N 2-chloro-1-(2,4-difluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CCl)C(F)=C1 UENGBOCGGKLVJJ-UHFFFAOYSA-N 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000003838 adenosines Chemical class 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 244000309464 bull Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000007429 general method Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 6
- GKOINNNTMHPDSY-IOSLPCCCSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(ethoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NOCC)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GKOINNNTMHPDSY-IOSLPCCCSA-N 0.000 description 5
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 102000018594 Tumour necrosis factor Human genes 0.000 description 5
- 108050007852 Tumour necrosis factor Proteins 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- 230000020176 deacylation Effects 0.000 description 5
- 238000005947 deacylation reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 230000006433 tumor necrosis factor production Effects 0.000 description 5
- RHUYHJGZWVXEHW-UHFFFAOYSA-N 1,1-Dimethyhydrazine Chemical compound CN(C)N RHUYHJGZWVXEHW-UHFFFAOYSA-N 0.000 description 4
- 229940122614 Adenosine receptor agonist Drugs 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- QLFWVDDEZQQVRQ-SDBHATRESA-N (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-2-piperidin-1-yloxolane-3,4-diol Chemical compound N1(CCCCC1)[C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC1=2 QLFWVDDEZQQVRQ-SDBHATRESA-N 0.000 description 3
- JDCGTCRTLUOWTP-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(piperidin-1-ylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3CCCCC3)=C2N=C1 JDCGTCRTLUOWTP-IDTAVKCVSA-N 0.000 description 3
- NYLHEAVZPYYUJZ-UHFFFAOYSA-N 1-methyl-1-(2-phenylethyl)hydrazine Chemical compound CN(N)CCC1=CC=CC=C1 NYLHEAVZPYYUJZ-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- 238000007360 debenzoylation reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 3
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 3
- XSSYCIGJYCVRRK-RQJHMYQMSA-N (-)-carbovir Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1C[C@H](CO)C=C1 XSSYCIGJYCVRRK-RQJHMYQMSA-N 0.000 description 2
- BIXYYZIIJIXVFW-UUOKFMHZSA-N (2R,3R,4S,5R)-2-(6-amino-2-chloro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BIXYYZIIJIXVFW-UUOKFMHZSA-N 0.000 description 2
- WJNPQSDKUNAQOU-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(cyclopentyloxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NOC3CCCC3)=C2N=C1 WJNPQSDKUNAQOU-IDTAVKCVSA-N 0.000 description 2
- NXIRSLRYLSFOHD-IOSLPCCCSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(methoxyamino)purin-9-yl]-5-ethenyloxolane-3,4-diol Chemical compound C1=NC=2C(NOC)=NC(Cl)=NC=2N1[C@@H]1O[C@H](C=C)[C@@H](O)[C@H]1O NXIRSLRYLSFOHD-IOSLPCCCSA-N 0.000 description 2
- PQMOKGJJYSHECH-SDBHATRESA-N (2r,3r,4s,5r)-2-[2-chloro-6-(piperidin-1-ylamino)purin-9-yl]-5-ethenyloxolane-3,4-diol Chemical compound O1[C@H](C=C)[C@@H](O)[C@@H](O)[C@@H]1N1C2=NC(Cl)=NC(NN3CCCCC3)=C2N=C1 PQMOKGJJYSHECH-SDBHATRESA-N 0.000 description 2
- BXZUVGVNTLFORS-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(piperidin-1-ylamino)purin-9-yl]-5-methyloxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C2=NC(Cl)=NC(NN3CCCCC3)=C2N=C1 BXZUVGVNTLFORS-IDTAVKCVSA-N 0.000 description 2
- ZUIVWUJDCHSHER-KQYNXXCUSA-N (2r,3r,4s,5s)-2-[2-chloro-6-(methoxyamino)purin-9-yl]-5-(chloromethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NOC)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CCl)[C@@H](O)[C@H]1O ZUIVWUJDCHSHER-KQYNXXCUSA-N 0.000 description 2
- CQTHHTYVWLTQER-SDBHATRESA-N (2r,3r,4s,5s)-2-[2-chloro-6-(piperidin-1-ylamino)purin-9-yl]-5-(methylsulfanylmethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC(Cl)=NC(NN3CCCCC3)=C2N=C1 CQTHHTYVWLTQER-SDBHATRESA-N 0.000 description 2
- RRRJKFMOKLWXEM-SCFUHWHPSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[2-methylsulfanyl-6-(2-phenoxyethoxyamino)purin-9-yl]oxolane-3,4-diol Chemical compound C=12N=CN([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=NC(SC)=NC=1NOCCOC1=CC=CC=C1 RRRJKFMOKLWXEM-SCFUHWHPSA-N 0.000 description 2
- YVIKQBLCJJEDRU-CNEMSGBDSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-phenylpurin-9-yl]oxolane-3,4-diol Chemical compound C1=NC=2C(NOC)=NC(C=3C=CC=CC=3)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YVIKQBLCJJEDRU-CNEMSGBDSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- LOGOEBMHHXYBID-WBKNRDRNSA-N (2s,3s,4r,5r)-5-[6-[(4-amino-3-iodanylphenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C([125I])C(N)=CC=3)=C2N=C1 LOGOEBMHHXYBID-WBKNRDRNSA-N 0.000 description 2
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 2
- RZQVEKFKCAVPKJ-UHFFFAOYSA-N 2-(2-phenylethoxy)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1OCCC1=CC=CC=C1 RZQVEKFKCAVPKJ-UHFFFAOYSA-N 0.000 description 2
- CIZPDRFTOOPDOB-SDBHATRESA-N 2-[(2r,3s,4r,5r)-5-[2-chloro-6-(piperidin-1-ylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]acetonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CC#N)O[C@H]1N1C2=NC(Cl)=NC(NN3CCCCC3)=C2N=C1 CIZPDRFTOOPDOB-SDBHATRESA-N 0.000 description 2
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 2
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 2
- NOTFZGFABLVTIG-UHFFFAOYSA-N Cyclohexylethyl acetate Chemical compound CC(=O)OCCC1CCCCC1 NOTFZGFABLVTIG-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- IZKJVVAPXGWCIF-JZJXAQOMSA-N [(2S,3R,4R,5S)-5-acetyloxy-4-benzoyloxy-2-(cyanomethyl)oxolan-3-yl] benzoate Chemical compound C(C)(=O)O[C@H]1[C@H](OC(C2=CC=CC=C2)=O)[C@H](OC(C2=CC=CC=C2)=O)[C@@H](O1)CC#N IZKJVVAPXGWCIF-JZJXAQOMSA-N 0.000 description 2
- WKSIBZZBSUBESO-KBIHSYGRSA-N [(2r,3r,4r)-4,5-diacetyloxy-2-(methoxymethyl)oxolan-3-yl] acetate Chemical compound COC[C@H]1OC(OC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O WKSIBZZBSUBESO-KBIHSYGRSA-N 0.000 description 2
- KPADVIZUJAOYTQ-WYKVRPKTSA-N [(2r,3r,4r)-4-benzoyloxy-2-ethenyl-5-methoxyoxolan-3-yl] benzoate Chemical compound O([C@@H]1[C@@H](C=C)OC([C@@H]1OC(=O)C=1C=CC=CC=1)OC)C(=O)C1=CC=CC=C1 KPADVIZUJAOYTQ-WYKVRPKTSA-N 0.000 description 2
- JYPYAXQMBYFUFS-LSCFUAHRSA-N [(2r,3r,4r,5r)-3,4-diacetyloxy-5-(6-chloro-2-methylpurin-9-yl)oxolan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C2=NC(C)=NC(Cl)=C2N=C1 JYPYAXQMBYFUFS-LSCFUAHRSA-N 0.000 description 2
- ZPGKWLKJXHFRJL-VBHAUSMQSA-N [(2r,3r,4r,5r)-3,4-dibenzoyloxy-5-(2,6-dichloropurin-9-yl)oxolan-2-yl]methyl benzoate Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1OC(=O)C=1C=CC=CC=1)OC(=O)C=1C=CC=CC=1)N1C=NC2=C(Cl)N=C(N=C21)Cl)OC(=O)C1=CC=CC=C1 ZPGKWLKJXHFRJL-VBHAUSMQSA-N 0.000 description 2
- DMKTUGHSKFENCH-SDBHATRESA-N [(2r,3r,4r,5r)-4-acetyloxy-5-[2-chloro-6-(methoxyamino)purin-9-yl]-2-(methoxymethyl)oxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC)O[C@H]1N1C2=NC(Cl)=NC(NOC)=C2N=C1 DMKTUGHSKFENCH-SDBHATRESA-N 0.000 description 2
- OETHLDHRCKMMNQ-HWFMHHSJSA-N [(2r,3r,4r,5s)-4-acetyloxy-5-[2-chloro-6-[(2-ethoxypyrrolidin-1-yl)amino]purin-9-yl]-2-(methoxymethyl)oxolan-3-yl] acetate Chemical compound CCOC1CCCN1NC1=NC(Cl)=NC2=C1N=CN2[C@@H]1[C@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC)O1 OETHLDHRCKMMNQ-HWFMHHSJSA-N 0.000 description 2
- HNIGJOPDRAQNCH-SCFUHWHPSA-N [(2s,3s,4r,5r)-4-acetyloxy-5-[2-chloro-6-(piperidin-1-ylamino)purin-9-yl]-2-(fluoromethyl)oxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(=O)C)[C@@H](CF)O[C@H]1N1C2=NC(Cl)=NC(NN3CCCCC3)=C2N=C1 HNIGJOPDRAQNCH-SCFUHWHPSA-N 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical compound CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- REYLNMLHVSCBDB-UHFFFAOYSA-N n-(7h-purin-2-yl)hydroxylamine Chemical class ONC1=NC=C2NC=NC2=N1 REYLNMLHVSCBDB-UHFFFAOYSA-N 0.000 description 2
- WIBADEXUNPVVIP-UHFFFAOYSA-N n-methyl-2-phenylethanamine;hydrochloride Chemical compound Cl.CNCCC1=CC=CC=C1 WIBADEXUNPVVIP-UHFFFAOYSA-N 0.000 description 2
- SASNBVQSOZSTPD-UHFFFAOYSA-N n-methylphenethylamine Chemical compound CNCCC1=CC=CC=C1 SASNBVQSOZSTPD-UHFFFAOYSA-N 0.000 description 2
- SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 description 2
- XUGWUUDOWNZAGW-UHFFFAOYSA-N neplanocin A Natural products C1=NC=2C(N)=NC=NC=2N1C1C=C(CO)C(O)C1O XUGWUUDOWNZAGW-UHFFFAOYSA-N 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 239000002342 ribonucleoside Substances 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 2
- 229950005741 rolipram Drugs 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- RIRGCFBBHQEQQH-SSFGXONLSA-N (-)-n6-(2-phenylisopropyl)adenosine Chemical compound C([C@@H](C)NC=1C=2N=CN(C=2N=CN=1)[C@H]1[C@@H]([C@H](O)[C@@H](CO)O1)O)C1=CC=CC=C1 RIRGCFBBHQEQQH-SSFGXONLSA-N 0.000 description 1
- UGRNVLGKAGREKS-GCXDCGAKSA-N (1r,2s,3r,5r)-3-(6-aminopurin-9-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1C[C@H](CO)[C@@H](O)[C@H]1O UGRNVLGKAGREKS-GCXDCGAKSA-N 0.000 description 1
- RCKORMYVZULMHP-IOSLPCCCSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-2-methoxyoxolane-3,4-diol Chemical compound C1=NC2=C(N)N=CN=C2N1[C@]1(OC)O[C@H](CO)[C@@H](O)[C@H]1O RCKORMYVZULMHP-IOSLPCCCSA-N 0.000 description 1
- XHRJGHCQQPETRH-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(Cl)=C2N=C1 XHRJGHCQQPETRH-KQYNXXCUSA-N 0.000 description 1
- DGKZTAGCCXJUAT-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-hydrazinylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NN)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O DGKZTAGCCXJUAT-KQYNXXCUSA-N 0.000 description 1
- TUQQCMYCSWRQCO-UUOKFMHZSA-N (2r,3r,4s,5r)-2-[2-amino-6-(hydroxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(N)=NC(NO)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TUQQCMYCSWRQCO-UUOKFMHZSA-N 0.000 description 1
- YVFOHTVUZVSHOO-WVSUBDOOSA-N (2r,3r,4s,5r)-2-[2-amino-6-[(4-phenylsulfanylpiperidin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=12N=CN([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=NC(N)=NC=1NN(CC1)CCC1SC1=CC=CC=C1 YVFOHTVUZVSHOO-WVSUBDOOSA-N 0.000 description 1
- WXOHKINLTMKOIK-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[2-bromo-6-(piperidin-1-ylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Br)=NC(NN3CCCCC3)=C2N=C1 WXOHKINLTMKOIK-IDTAVKCVSA-N 0.000 description 1
- ZVIPVFYOHIIKSZ-XTMLTMLVSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(1,2,3,4-tetrahydronaphthalen-1-yloxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NOC3C4=CC=CC=C4CCC3)=C2N=C1 ZVIPVFYOHIIKSZ-XTMLTMLVSA-N 0.000 description 1
- UTUDZONPKFZBLM-IOSLPCCCSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(2,2-dimethylhydrazinyl)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NN(C)C)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UTUDZONPKFZBLM-IOSLPCCCSA-N 0.000 description 1
- KWVFYTKWZYIRTI-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(2-phenoxyethoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NOCCOC=3C=CC=CC=3)=C2N=C1 KWVFYTKWZYIRTI-LSCFUAHRSA-N 0.000 description 1
- UYGAZXWDBAVZNN-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(2-phenylethoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NOCCC=3C=CC=CC=3)=C2N=C1 UYGAZXWDBAVZNN-LSCFUAHRSA-N 0.000 description 1
- AJQBSVAXODDVFF-UUOKFMHZSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(hydroxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NO)=C2N=C1 AJQBSVAXODDVFF-UUOKFMHZSA-N 0.000 description 1
- MQFYCJARQKDNLT-IOSLPCCCSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(methoxyamino)purin-9-yl]-5-(methoxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](COC)O[C@H]1N1C2=NC(Cl)=NC(NOC)=C2N=C1 MQFYCJARQKDNLT-IOSLPCCCSA-N 0.000 description 1
- DVNCUOILHKIERN-XNIJJKJLSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(phenylmethoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NOCC=3C=CC=CC=3)=C2N=C1 DVNCUOILHKIERN-XNIJJKJLSA-N 0.000 description 1
- HRLNZLIFPBRASC-WOUKDFQISA-N (2r,3r,4s,5r)-2-[2-chloro-6-(propoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NOCCC)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HRLNZLIFPBRASC-WOUKDFQISA-N 0.000 description 1
- AAGQKJLVWSVKQD-FPMMIGMHSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(2-ethoxypyrrolidin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound CCOC1CCCN1NC1=NC(Cl)=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 AAGQKJLVWSVKQD-FPMMIGMHSA-N 0.000 description 1
- JWCAEKYVCQJQFV-WOUKDFQISA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(2-methylpropan-2-yl)oxyamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NOC(C)(C)C)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JWCAEKYVCQJQFV-WOUKDFQISA-N 0.000 description 1
- YVYYFPZNCAKOAK-YXYADJKSSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(3-methoxypiperidin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1C(OC)CCCN1NC1=NC(Cl)=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 YVYYFPZNCAKOAK-YXYADJKSSA-N 0.000 description 1
- YOEXNQZGJPAMKT-WVSUBDOOSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(4-phenylpiperidin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3CCC(CC3)C=3C=CC=CC=3)=C2N=C1 YOEXNQZGJPAMKT-WVSUBDOOSA-N 0.000 description 1
- KICREECGNIOOCT-QHEVOPSZSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(4-phenylsulfanylcyclohexyl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NC3CCC(CC3)SC=3C=CC=CC=3)=C2N=C1 KICREECGNIOOCT-QHEVOPSZSA-N 0.000 description 1
- WSZACYCPTUPOKE-UUOKFMHZSA-N (2r,3r,4s,5r)-2-[2-fluoro-6-(hydroxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(F)=NC(NO)=C2N=C1 WSZACYCPTUPOKE-UUOKFMHZSA-N 0.000 description 1
- WQLDOSXSFZYWRA-XNIJJKJLSA-N (2r,3r,4s,5r)-2-[6-(cyclopentyloxyamino)-2-methylpurin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=12N=CN([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=NC(C)=NC=1NOC1CCCC1 WQLDOSXSFZYWRA-XNIJJKJLSA-N 0.000 description 1
- XLEKNHGPWVDAMJ-WOUKDFQISA-N (2r,3r,4s,5r)-2-[6-(ethoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NOCC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O XLEKNHGPWVDAMJ-WOUKDFQISA-N 0.000 description 1
- QROZCFCNYCVEDO-KQYNXXCUSA-N (2r,3r,4s,5r)-2-[6-(hydroxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NO)=C2N=C1 QROZCFCNYCVEDO-KQYNXXCUSA-N 0.000 description 1
- CNTAVKSOKGBUOU-IDTAVKCVSA-N (2r,3r,4s,5s)-2-[2-chloro-6-(cyclopentyloxyamino)purin-9-yl]-5-(chloromethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CCl)O[C@H]1N1C2=NC(Cl)=NC(NOC3CCCC3)=C2N=C1 CNTAVKSOKGBUOU-IDTAVKCVSA-N 0.000 description 1
- LFAFBZSLVZMZIT-XNIJJKJLSA-N (2r,3r,4s,5s)-2-[2-chloro-6-(phenylmethoxyamino)purin-9-yl]-5-(fluoromethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CF)O[C@H]1N1C2=NC(Cl)=NC(NOCC=3C=CC=CC=3)=C2N=C1 LFAFBZSLVZMZIT-XNIJJKJLSA-N 0.000 description 1
- HSSKHSYCZVCMLU-IDTAVKCVSA-N (2r,3r,4s,5s)-2-[2-chloro-6-(piperidin-1-ylamino)purin-9-yl]-5-(fluoromethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CF)O[C@H]1N1C2=NC(Cl)=NC(NN3CCCCC3)=C2N=C1 HSSKHSYCZVCMLU-IDTAVKCVSA-N 0.000 description 1
- CTSKDDVSAVXUHB-YXYADJKSSA-N (2r,3r,4s,5s)-2-[2-chloro-6-[(3-methoxypiperidin-1-yl)amino]purin-9-yl]-5-(chloromethyl)oxolane-3,4-diol Chemical compound C1C(OC)CCCN1NC1=NC(Cl)=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CCl)O1 CTSKDDVSAVXUHB-YXYADJKSSA-N 0.000 description 1
- XAMXDJSZPJGIKW-FOALSCLJSA-N (2r,3r,4s,5s)-2-[6-[[4-(benzenesulfinyl)piperidin-1-yl]amino]-2-chloropurin-9-yl]-5-(chloromethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CCl)O[C@H]1N1C2=NC(Cl)=NC(NN3CCC(CC3)S(=O)C=3C=CC=CC=3)=C2N=C1 XAMXDJSZPJGIKW-FOALSCLJSA-N 0.000 description 1
- VMOZLWKIEHKCGN-SDBHATRESA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[2-methylsulfanyl-6-(piperidin-1-ylamino)purin-9-yl]oxolane-3,4-diol Chemical compound C=12N=CN([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=NC(SC)=NC=1NN1CCCCC1 VMOZLWKIEHKCGN-SDBHATRESA-N 0.000 description 1
- ORBBAWPEINOUJR-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(2-methylhydrazinyl)purin-9-yl]oxolane-3,4-diol Chemical compound C1=NC=2C(NNC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ORBBAWPEINOUJR-IOSLPCCCSA-N 0.000 description 1
- OQTMCTGDNWPWNU-WOUKDFQISA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-methylpurin-9-yl]oxolane-3,4-diol Chemical compound C1=NC=2C(NOC)=NC(C)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OQTMCTGDNWPWNU-WOUKDFQISA-N 0.000 description 1
- YRWOZNWCGLAHSD-LSCFUAHRSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(phenylmethoxyamino)purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NOCC=3C=CC=CC=3)=C2N=C1 YRWOZNWCGLAHSD-LSCFUAHRSA-N 0.000 description 1
- BWSIKGOGLDNQBZ-LURJTMIESA-N (2s)-2-(methoxymethyl)pyrrolidin-1-amine Chemical compound COC[C@@H]1CCCN1N BWSIKGOGLDNQBZ-LURJTMIESA-N 0.000 description 1
- SNPISNLSEAYTOA-ORYJOLLOSA-N (2s,3r,4s,5r)-2-[2-chloro-6-[(2-ethoxypyrrolidin-1-yl)amino]purin-9-yl]-5-(methoxymethyl)oxolane-3,4-diol Chemical compound CCOC1CCCN1NC1=NC(Cl)=NC2=C1N=CN2[C@@H]1[C@H](O)[C@H](O)[C@@H](COC)O1 SNPISNLSEAYTOA-ORYJOLLOSA-N 0.000 description 1
- YBCSNCCRJXUBIF-ZJSOHHELSA-N (2s,3r,4s,5s)-2-[2-chloro-6-[(2-ethoxypyrrolidin-1-yl)amino]purin-9-yl]-5-(chloromethyl)oxolane-3,4-diol Chemical compound CCOC1CCCN1NC1=NC(Cl)=NC2=C1N=CN2[C@@H]1[C@H](O)[C@H](O)[C@@H](CCl)O1 YBCSNCCRJXUBIF-ZJSOHHELSA-N 0.000 description 1
- YRMFOLJVQAWNAO-IDTAVKCVSA-N (2s,3s,4r,5r)-2-(bromomethyl)-5-[2-chloro-6-(piperidin-1-ylamino)purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CBr)O[C@H]1N1C2=NC(Cl)=NC(NN3CCCCC3)=C2N=C1 YRMFOLJVQAWNAO-IDTAVKCVSA-N 0.000 description 1
- JPIKERNONDNLQR-WVSUBDOOSA-N (2s,3s,4r,5r)-2-(chloromethyl)-5-[2-chloro-6-[(4-phenoxypiperidin-1-yl)amino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CCl)O[C@H]1N1C2=NC(Cl)=NC(NN3CCC(CC3)OC=3C=CC=CC=3)=C2N=C1 JPIKERNONDNLQR-WVSUBDOOSA-N 0.000 description 1
- UJPHTPZBKQPVGF-WVSUBDOOSA-N (2s,3s,4r,5r)-2-(chloromethyl)-5-[2-chloro-6-[(4-phenylpiperidin-1-yl)amino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CCl)O[C@H]1N1C2=NC(Cl)=NC(NN3CCC(CC3)C=3C=CC=CC=3)=C2N=C1 UJPHTPZBKQPVGF-WVSUBDOOSA-N 0.000 description 1
- SYQFCKHROVUKBU-QHEVOPSZSA-N (2s,3s,4r,5r)-2-(chloromethyl)-5-[2-chloro-6-[(4-phenylsulfanylcyclohexyl)amino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CCl)O[C@H]1N1C2=NC(Cl)=NC(NC3CCC(CC3)SC=3C=CC=CC=3)=C2N=C1 SYQFCKHROVUKBU-QHEVOPSZSA-N 0.000 description 1
- ZWMXNEWPLAOIAZ-WVSUBDOOSA-N (2s,3s,4r,5r)-2-(chloromethyl)-5-[2-chloro-6-[(4-phenylsulfanylpiperidin-1-yl)amino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CCl)O[C@H]1N1C2=NC(Cl)=NC(NN3CCC(CC3)SC=3C=CC=CC=3)=C2N=C1 ZWMXNEWPLAOIAZ-WVSUBDOOSA-N 0.000 description 1
- PLYRYAHDNXANEG-QMWPFBOUSA-N (2s,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 PLYRYAHDNXANEG-QMWPFBOUSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- HJPRDDKCXVCFOH-UHFFFAOYSA-N 1,3-dibutyl-7-(2-oxopropyl)purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1N(CC(C)=O)C=N2 HJPRDDKCXVCFOH-UHFFFAOYSA-N 0.000 description 1
- YMYOTLFVNNQUIC-UHFFFAOYSA-N 1-methyl-1-(2-phenoxyethyl)hydrazine Chemical compound CN(N)CCOC1=CC=CC=C1 YMYOTLFVNNQUIC-UHFFFAOYSA-N 0.000 description 1
- MWOODERJGVWYJE-UHFFFAOYSA-N 1-methyl-1-phenylhydrazine Chemical compound CN(N)C1=CC=CC=C1 MWOODERJGVWYJE-UHFFFAOYSA-N 0.000 description 1
- HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 1
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical class C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 1
- XVESZHYVMBVOFE-DBRKOABJSA-N 2-[(2r,3s,4r,5r)-3,4-dihydroxy-5-methoxyoxolan-2-yl]acetonitrile Chemical compound CO[C@@H]1O[C@H](CC#N)[C@@H](O)[C@H]1O XVESZHYVMBVOFE-DBRKOABJSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OTDJAMXESTUWLO-UUOKFMHZSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-3H-purine-6-thione Chemical compound C12=NC(N)=NC(S)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OTDJAMXESTUWLO-UUOKFMHZSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- MNNZINNZIQVULG-UHFFFAOYSA-N 2-chloroethylbenzene Chemical compound ClCCC1=CC=CC=C1 MNNZINNZIQVULG-UHFFFAOYSA-N 0.000 description 1
- BTTUXUIQQBLIQE-UHFFFAOYSA-N 2-fluoro-7h-purine Chemical compound FC1=NC=C2NC=NC2=N1 BTTUXUIQQBLIQE-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- IYSNPOMTKFZDHZ-KQYNXXCUSA-N 5'-chloro-5'-deoxyadenosine Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CCl)[C@@H](O)[C@H]1O IYSNPOMTKFZDHZ-KQYNXXCUSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- IUEISQYNCXVHTJ-UHFFFAOYSA-N 7h-purin-6-ylhydrazine Chemical group NNC1=NC=NC2=C1NC=N2 IUEISQYNCXVHTJ-UHFFFAOYSA-N 0.000 description 1
- SOTIPZUHKSPAMN-IOSLPCCCSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-methyl-3h-purin-6-one Chemical compound C12=NC(C)=NC(O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SOTIPZUHKSPAMN-IOSLPCCCSA-N 0.000 description 1
- 229930024421 Adenine Chemical class 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 229940103988 Adenosine uptake inhibitor Drugs 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 229930186232 Aristeromycin Natural products 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- SRXCRBPUBJKBJA-KRZXBLKESA-N C(C1=CC=CC=C1)(=O)[C@@]1([C@H](OC)O[C@@H]([C@H]1OC(C1=CC=CC=C1)=O)CC#N)O Chemical compound C(C1=CC=CC=C1)(=O)[C@@]1([C@H](OC)O[C@@H]([C@H]1OC(C1=CC=CC=C1)=O)CC#N)O SRXCRBPUBJKBJA-KRZXBLKESA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- KFFMNTMEOXANRS-UHFFFAOYSA-N N1C=NC=C2C=NC=C21 Chemical group N1C=NC=C2C=NC=C21 KFFMNTMEOXANRS-UHFFFAOYSA-N 0.000 description 1
- 101150101537 Olah gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 241001237728 Precis Species 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- IZKJVVAPXGWCIF-NBPUOTKHSA-N [(2S,3R,4R)-5-acetyloxy-4-benzoyloxy-2-(cyanomethyl)oxolan-3-yl] benzoate Chemical compound C(C)(=O)OC1[C@H](OC(C2=CC=CC=C2)=O)[C@H](OC(C2=CC=CC=C2)=O)[C@@H](O1)CC#N IZKJVVAPXGWCIF-NBPUOTKHSA-N 0.000 description 1
- KJUBLVPLEIPFQR-NBPUOTKHSA-N [(2S,3R,4R)-5-acetyloxy-4-benzoyloxy-2-ethenyloxolan-3-yl] benzoate Chemical compound C(C)(=O)OC1[C@H](OC(C2=CC=CC=C2)=O)[C@H](OC(C2=CC=CC=C2)=O)[C@@H](O1)C=C KJUBLVPLEIPFQR-NBPUOTKHSA-N 0.000 description 1
- HOKIFLYHNPKFGY-DEPLMIEDSA-N [(2S,3R,4R)-5-acetyloxy-4-benzoyloxy-2-methyloxolan-3-yl] benzoate Chemical compound C(C)(=O)OC1[C@H](OC(C2=CC=CC=C2)=O)[C@H](OC(C2=CC=CC=C2)=O)[C@@H](O1)C HOKIFLYHNPKFGY-DEPLMIEDSA-N 0.000 description 1
- WLHOVGKSTWSMOM-WLEDDMDJSA-N [(2r,3r,4r)-4-benzoyloxy-5-methoxy-2-methyloxolan-3-yl] benzoate Chemical compound O([C@@H]1[C@@H](C)OC([C@@H]1OC(=O)C=1C=CC=CC=1)OC)C(=O)C1=CC=CC=C1 WLHOVGKSTWSMOM-WLEDDMDJSA-N 0.000 description 1
- JDCZDQCEZBSYEB-XNIJJKJLSA-N [(2r,3r,4r,5r)-3,4-diacetyloxy-5-(6-chloro-2-methylsulfanylpurin-9-yl)oxolan-2-yl]methyl acetate Chemical compound C12=NC(SC)=NC(Cl)=C2N=CN1[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O JDCZDQCEZBSYEB-XNIJJKJLSA-N 0.000 description 1
- GQDFHQPHOSIYOP-UVLLPENVSA-N [(2r,3r,4r,5r)-3,4-diacetyloxy-5-(6-chloro-2-phenylpurin-9-yl)oxolan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C2=NC(C=3C=CC=CC=3)=NC(Cl)=C2N=C1 GQDFHQPHOSIYOP-UVLLPENVSA-N 0.000 description 1
- MSDUECFSJYTGMO-QSYCCZFCSA-N [(2r,3r,4r,5r)-3,4-dibenzoyloxy-5-[2-chloro-6-(2-phenylethoxyamino)purin-9-yl]oxolan-2-yl]methyl benzoate Chemical compound C=12N=CN([C@H]3[C@@H]([C@H](OC(=O)C=4C=CC=CC=4)[C@@H](COC(=O)C=4C=CC=CC=4)O3)OC(=O)C=3C=CC=CC=3)C2=NC(Cl)=NC=1NOCCC1=CC=CC=C1 MSDUECFSJYTGMO-QSYCCZFCSA-N 0.000 description 1
- VGHKEEBQHDJGTJ-NEYJZJCJSA-N [(2r,3r,4r,5r)-4-benzoyloxy-2-(cyanomethyl)-5-methoxyoxolan-3-yl] benzoate Chemical compound O([C@@H]1[C@@H](CC#N)O[C@H]([C@@H]1OC(=O)C=1C=CC=CC=1)OC)C(=O)C1=CC=CC=C1 VGHKEEBQHDJGTJ-NEYJZJCJSA-N 0.000 description 1
- ZUVQJGAEVJVSAG-UMCMBGNQSA-N [(2s,3s,4r,5r)-4-acetyloxy-2-(chloromethyl)-5-[2-chloro-6-[(4-phenylsulfanylpiperidin-1-yl)amino]purin-9-yl]oxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(=O)C)[C@@H](CCl)O[C@H]1N1C2=NC(Cl)=NC(NN3CCC(CC3)SC=3C=CC=CC=3)=C2N=C1 ZUVQJGAEVJVSAG-UMCMBGNQSA-N 0.000 description 1
- BIGPGQAMXJZLRD-WVSUBDOOSA-N [(2s,3s,4r,5r)-4-acetyloxy-5-[2-chloro-6-(phenylmethoxyamino)purin-9-yl]-2-(fluoromethyl)oxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(=O)C)[C@@H](CF)O[C@H]1N1C2=NC(Cl)=NC(NOCC=3C=CC=CC=3)=C2N=C1 BIGPGQAMXJZLRD-WVSUBDOOSA-N 0.000 description 1
- JTJDRTPCJBDESZ-UMCMBGNQSA-N [(2s,3s,4r,5r)-4-acetyloxy-5-[6-[[4-(benzenesulfonyl)piperidin-1-yl]amino]-2-chloropurin-9-yl]-2-(chloromethyl)oxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(=O)C)[C@@H](CCl)O[C@H]1N1C2=NC(Cl)=NC(NN3CCC(CC3)S(=O)(=O)C=3C=CC=CC=3)=C2N=C1 JTJDRTPCJBDESZ-UMCMBGNQSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002593 adenosine A3 receptor agonist Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 230000005792 cardiovascular activity Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- FPUGCISOLXNPPC-IOSLPCCCSA-N cordysinin B Chemical class CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-IOSLPCCCSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 229950004687 denbufylline Drugs 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- XIQUJVRFXPBMHS-UHFFFAOYSA-N hydron;o-prop-2-enylhydroxylamine;chloride Chemical compound Cl.NOCC=C XIQUJVRFXPBMHS-UHFFFAOYSA-N 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000007302 negative regulation of cytokine production Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- WOXGREIMSJFDPG-UHFFFAOYSA-N o-(2-methylpropyl)hydroxylamine;hydrochloride Chemical compound Cl.CC(C)CON WOXGREIMSJFDPG-UHFFFAOYSA-N 0.000 description 1
- CAYJVHLVJHHERP-UHFFFAOYSA-N o-(2-phenoxyethoxy)hydroxylamine;hydrochloride Chemical compound Cl.NOOCCOC1=CC=CC=C1 CAYJVHLVJHHERP-UHFFFAOYSA-N 0.000 description 1
- HWKGEDJHAMSGKI-UHFFFAOYSA-N o-(2-phenoxyethyl)hydroxylamine Chemical compound NOCCOC1=CC=CC=C1 HWKGEDJHAMSGKI-UHFFFAOYSA-N 0.000 description 1
- MUPSJLRUCGYRTR-UHFFFAOYSA-N o-(2-phenylethyl)hydroxylamine;hydrochloride Chemical compound Cl.NOCCC1=CC=CC=C1 MUPSJLRUCGYRTR-UHFFFAOYSA-N 0.000 description 1
- OJYSJFUYARGLPG-UHFFFAOYSA-N o-[(4-nitrophenyl)methyl]hydroxylamine Chemical compound NOCC1=CC=C([N+]([O-])=O)C=C1 OJYSJFUYARGLPG-UHFFFAOYSA-N 0.000 description 1
- HWWCBAWGNJYHPP-UHFFFAOYSA-N o-cyclopentylhydroxylamine Chemical compound NOC1CCCC1 HWWCBAWGNJYHPP-UHFFFAOYSA-N 0.000 description 1
- KBYLNXKSGMLDDM-UHFFFAOYSA-N o-cyclopentylhydroxylamine;hydrochloride Chemical compound Cl.NOC1CCCC1 KBYLNXKSGMLDDM-UHFFFAOYSA-N 0.000 description 1
- NUXCOKIYARRTDC-UHFFFAOYSA-N o-ethylhydroxylamine;hydron;chloride Chemical compound Cl.CCON NUXCOKIYARRTDC-UHFFFAOYSA-N 0.000 description 1
- ZBDXGNXNXXPKJI-UHFFFAOYSA-N o-tert-butylhydroxylamine;hydrochloride Chemical compound Cl.CC(C)(C)ON ZBDXGNXNXXPKJI-UHFFFAOYSA-N 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940100595 phenylacetaldehyde Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 230000001696 purinergic effect Effects 0.000 description 1
- 102000008344 purinergic nucleotide receptor activity proteins Human genes 0.000 description 1
- 108040002778 purinergic nucleotide receptor activity proteins Proteins 0.000 description 1
- 239000003422 purinergic receptor affecting agent Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000008259 solid foam Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- UIJXHKXIOCDSEB-UHFFFAOYSA-N tert-butyl 3-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(O)C1 UIJXHKXIOCDSEB-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- ADZJWYULTMTLQZ-UHFFFAOYSA-N tritylphosphane;hydrobromide Chemical compound [Br-].C=1C=CC=CC=1C(C=1C=CC=CC=1)([PH3+])C1=CC=CC=C1 ADZJWYULTMTLQZ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Definitions
- the present invention relates to a method of treating disorders related to cytokines in humans, including autoimmune disorders, iriflammation, arthritis, type I or type LI diabetes, multiple schlerosis, stroke, osteoporosis, septic shock and menstrual complications.
- the invention furthermore relates to the use of known and new purine derivatives for the manufacture of a pharmaceutical composition for treating the above diseases as well as new purine derivatives having affinity for subtypes of adenosine receptors and acting as cytokine inhibitors.
- Adenosine receptors represent a subclass (Pi) of the group of purine nucleotide and nucleoside receptors known as purinoreceptors. This subclass has been further classified into distinct receptor types which are now known as Ai, A ⁇ , A 2b and A 3 .
- Adenosine A 3 receptors Pharmacological Properties, Species Differences and Receptor Functions. ⁇ PS 1994, 15, 298-306; Jacobson, K.A.; Kim, H.A.; Siddiqi, S.M.; Olah, M.E., Stiles, G.L.; von Lubitz, D..K.J.E.; A3 Adenosine Receptors: Design of Selective Ligands and Therapeutic Propects. Drugs of the Future 1995, 20, 689-699; Collis, M.G.; Hourani, S.M.O.; Adenosine Receptor Subtypes, ⁇ PS 1993, 360-366].
- cytokine production Cerri, M.A.; Beltran-Nunez, A.; Bernasconi, S.; Dejana, E.; Bassi, L.; Bazzoni, G. Inhibition of Cytokine Production and Endothelial Expression of Adhesion Antigens by 5'- Methylthioadenosine. Eur. J. Pharmacol. 1993, 232, 291-294).
- adenosine agonists R-PIA, NEC A, CPCA, CGS 21680, 2-chloroadenosine and CHA have all been shown to have an inhibitory effect on Tumour Necrosis Factor (TNF) production (Le Vraux, V.; Chen, Y.L.; Masson, M.; De Sousa, M.; Giroud, J P.; Florentin, I.; Chauvelot-Moachon, L. Inhibition of Human Monocyte TNF production by Adenosine Receptor Agonists. Life Sci.
- TNF Tumour Necrosis Factor
- Circulatory Shock 1995, 44, 97-103 as has their therapeutic potential (Giroud, J.P.; Lian Chen, Y.; Le Vraux, V.; Chauvelot- Moachon, L. Therapeutic Aspects of Adenosine in Relation to its anti-TNF properties. Bull. Acad Natl. Med (Paris) 1995, 179, 79 -101).
- TNF- ⁇ inhibitors are useful in the treatment of diabetes (Argiles, J.M., Lopez-Soriano, J. and Lopez-Soriano, F.J. Cytokines and Diabetes: The Final Step. Involvement of TNF- ⁇ in both Type I and Type U Diabetes Mellitus. Horm. Metab. Res., 1994, 26, 447 - 449).
- TNF- ⁇ levels are increased in obese rodents (Yamakawa, T., Tanaka, S-L, Yamakawa, Y., Kiuchi, Y., Isoda, F., Kawamoto, S, Okuda, K. and Sekihara, H. Augmented Production of Tumor Necrosis Factor- ⁇ Production in Obese Mice. Clin. Immunol, and Immunopath., 1995, 75, 51-56).
- a clinical study of the expression pattern of TNF- ⁇ in adipose tissue of obese and normal premenopausal women has been carried out (Hotamisligil, G.S., Amer, P. Caro, J.F., Atkinson, R.L.
- adenosine and adenosine agonists acting via A receptors can be of benefit in for example septic shock or ischaemia-reperfusion injury, where cytokine production by mononuclear phagocytes can be inhibited by these agents (Bouma, M.G., Stad, R.K., van den
- TNF- ⁇ inhibitors have application in disorders which involve an inflammatory response, but this cytokine has multiple inflammatory, metabolic and immunological activities (Jirillo, E. Pellegrino, N.M. and Antonaci, S. Role of Tumor Necrosis Factor- ⁇ in Physiological and Pathological Conditions. Med Sci. Res., 1995, 23, 75-79).
- TNF- ⁇ inhibitors such as rolipram, pentoxyfylline and denbufylline are phosphodiesterase (PDE) inhibitors and exert their effects on TNF- ⁇ via control of cAMP (Davidsen, S.K. and Summers, J.B. Inhibitors of TNF- ⁇ Synthesis. Exp. Opin. Ther. Patents 1995, 5, 1087 - 1100).
- PDE phosphodiesterase
- Evidence is also available for some synergism between the effects of rolipram and adenosine in reduction of T primed neutrophil oxidative activity, thereby offering protection against inflammatory tissue damage (Sullivan, G, Ca ⁇ er, H.T. and Mandell, GL. Int. J. Immunopharmac. 1995, 17, 793-803).
- TNF inhibitors in the prevention of neuronal damage following cerebral ischaemia (Firestein, G.Z., Liu, T and Barone, F.C. Cytokines, Inflammation, and Brain Injury: Role of Tumor Necrosis Factor- ⁇ . Cerebrovascular and Brain Metabolism Reviews 1994, 6, 341-360).
- Examples with hydrogen at the purine 2-position include N-aminoadenosine, N-[(N-methyl-N- phenyl)amino]adenosine, N-hydroxyadenosine, JV-methoxyadenosine and N-benzyloxyadenosine (Kusachi, S., Thompson, R.D. Bugni, W.J., Yamada, N. and Olsson, R.A. Dog Coronary Artery Adenosine Receptor: Structure of the ⁇ -Alkyl Subregion. J.
- N-ethoxyadenosine (Fuj ⁇ , T., Wu, C.C, Itaya, T., Moro, S. and Saito, T. Purines.
- XI The Synthesis of N-Alkoxyadenosines and Their 2',3'-O-Isopropylidene Derivatives Chem Pharm.
- Examples of adenosine derivatives with oxygen or nitrogen atoms bonded to the 6-am ⁇ no substituent, containing an additional purine 2-subst ⁇ tuent are 2-amino-N-hydroxyadenosine (Kikugawa, K , Iizuka, K , Higuchi, Y , Hirayama, H and Ichino, M Platelet Aggregation Inhibitors 2 Inhibition of Platelet Aggregation by 5'-,2-,6-, and 8-substituted Adenosines J.
- Pfizer Inc. claim a range of heterocycles, including some purine derivatives, as CRF antagonists.
- ribose moiety in adenosine is chemically modified, and many of those known have poor affinity for the adenosine receptor (Taylor, M.D., Moos, W.H., Hamilton, H.W. Szotek, D.S. PAtt, W.C. Badger, E.W. Bristol, J.W. Bruns, R.F. Heffher, T.G. Mertz, T.E. Ribose-Modified Adenosine Analogues as Adenosine Receptor Agonists. J. Med Chem., 1986, 29, 346-353).
- adenosine A 3 receptor agonists are 5'-modified adenosine derivatives (Jacobson, K.A.; Kim, HA; Siddiqi, S.M.; Olah, M.E.; Stiles, G.L.; von Lubitz, D..K.J.E.; A 3 Adenosine Receptors: Design of Selective Ligands and Therapeutic Propects. Drugs of the Future 1995, 20, 689-699; Baraldi, P.G., Cacciari, B., Spalluto, G. Ji, X-d, Olah, M.E.
- EP-A-181,128 and EP-A-181,129 disclose 5 -deoxy adenosine derivatives containing 5'- hydrogen, 5'-halogen and 5 -methylthio, which are claimed to have desirable anti-inflammatory, analgesic as well as CNS and antihypertensive properties respectively.
- EP-A-232,813 discloses N-substituted adenosines including a larger range of 5'-modified compounds.
- WO 88/03147 5'-substituted adenosine derivatives with selectivity for the adenosine A 2 receptor are disclosed.
- EP Publication No. 0 423 777 A2 a method for treating gastrointestinal motility disorders using N(6) (substituted aminoalkyl) adenosine derivatives is disclosed.
- EP Publication No. 0 490 818 Al describes a new use of 2'-O-methyl adenosine derivatives for a range of ailments including neurodegenerative disorders.
- the compounds of WO 93/23417 and WO 95/07921 and some closely related compounds have been found to be cytokine inhibitors, for example inhibitors of TNF- ⁇ , and are found to be useful in the treatment of disorders related to cytokines in mammals, including humans. These conditions include inflammation, arthritis, type I and type LI diabetes, autoimmune disorders, multiple schlerosis, stroke, osteoporosis, septic shock and menstrual complications.
- the present invention relates to a new use of adenosine analogues containing both ribose and modified ribose moieties, some of which are disclosed in WO 93/23417 and WO 95/07921, which show potent binding to adenosine receptors.
- the present invention relates to a method of treating disorders related to cytokines in mammals comprising administering to a mammal in need thereof an effective amount of a compound of the general formula (I), or a pharmaceutically acceptable salt thereof:
- X represents hydrogen, halogen, a ino, perhalomethyl, cyano, C w -alkyl, C ⁇ -alkoxy, -s- alkylthio, Ci-6-alkylarn.no or phenyl;
- A is hydroxymethyl, methyl, chloromethyl, bromomethyl, fluoromethyl, cyanomethyl, aminomethyl, vinyl, methylthiomethyl or methoxymethyl;
- Ri is selected from the groups consisting of
- n is 1 to 3 and where the group (a) may be optionally substituted with one or two Ci-s-alkyl groups, C M -alkenyl, C ⁇ -alkynyl, phenoxy, phenylsulphonyl, phenylthio, hydroxy, phenyl, d- ⁇ -alkoxy or C ⁇ -alkoxy- Ci- ⁇ -alkyl, phenylthioalkyl or
- Y is O, S or NZ, where Z is H, C ⁇ -6-alkyl or phenyl, and where the group (b) may be optionally substituted with C -6-alkenyl, C 2- 6-alkynyl, phenoxy, phenyl, or
- R s -NR ⁇ or-YR 4 wherein Y is oxygen; R 2 is C ⁇ -alkyl;
- R 3 is phenyl or which may be substituted by phenyl or phenoxy;
- R 4 is straight-chain C ⁇ -6-alkyl, branched C3-8-alkyl, C 2 .g-alkenyl or C3.8-cycloalkyl, which may be substituted by phenyl or phenoxy which in turn may be substituted with nitro, halogen or amine.
- a preferred method of treating disorders involving cytokines comprises administering to a subject in need thereof a compound of the above general formula (I) wherein R 1 is -OR 4 , wherein R 4 is straight-chain branched C 3 .8-a.kyl, C 2 . 8 -alkenyl or C3-g-cycloalkyl, which may be substi ⁇ tuted by phenyl or phenoxy which in turn may be substituted with nitro, halogen or amine.
- the present invention is furthermore concerned with new compounds of the above formula (I) or pharmaceutically acceptable salts thereof, wherein
- X represents phenyl
- A is hydroxymethyl, methyl, chloromethyl, bromomethyl, fluoromethyl, cyanomethyl, aminomethyl, vinyl, methylthiomethyl or methoxymethyl; i is selected from the groups consisting of
- n is 1 to 3 and where the group (a) may be optionally substituted with one or two Ci-s-alkyl groups, C 2- 6-alkenyl, C 2 ⁇ -alkynyl, phenoxy, phenylsulphonyl, phenylthio, hydroxy, phenyl, C ⁇ -alkoxy or Ci-e-alkoxy-C -alkyl, phenylthioalkyl or
- Y is O, S or NZ, where Z is H, or phenyl, and where the group (b) may be optionally substituted with Ci- ⁇ -alkyl, C w -alkenyl, C 2 -5-alkynyl, phenoxy, phenyl, C ⁇ -alkoxy or
- R' is -NR 2 R 3 or -YR 4 , wherein Y is oxygen; R 2 is Cw-alkyl;
- R 3 is phenyl or C w -alkyl which may be substituted by phenyl or phenoxy;
- R 4 is straight-chain Ci- ⁇ -alkyi, branched C 3 -8-alkyl, C 2 .8-alkenyl or C3-8-cycloalkyl, which may be substituted by phenyl or phenoxy which in rum may be substituted with nitro, halogen or amine.
- the present invention is furthermore concerned with new compounds of the above formula (I) or pharmaceutically acceptable salts thereof, wherein
- X represents hydrogen, halogen, arnino, perhalomethyl, cyano, Cns-alkyl, C 1 - 5 - alkylthio, or phenyl;
- A is hydroxymethyl, methyl, chloromethyl, bromomethyl, fluoromethyl, cyanomethyl, aminomethyl, vinyl, methylthiomethyl or methoxymethyl;
- Ri is selected from the groups consisting of
- n is 1 to 3 and where the group (a) may be optionally substituted with one or two Ci- ⁇ -alkyl groups, C -6-alkenyl, C 2-6 -alkynyl, phenoxy, phenylsulphonyl, phenylthio, hydroxy, phenyl, C ⁇ -alkoxy or Ci- ⁇ -alkoxy- C e -alkyl, phenylthioalkyl or
- Y is O, S or NZ, where Z is H, or phenyl, and where the group (b) may be optionally substituted with or Ci- ⁇ -alkoxy-Ci- ⁇ -alkyl, or R 1 is -NR 2 R 3 or -YR 4 , wherein Y is oxygen;
- R 2 is C ⁇ -6-alkyl
- R 3 is phenyl or C ⁇ -6-alkyl which may be substituted by phenyl or phenoxy;
- R 4 is branched C 3 .g-alkyl or C 2 .8-alkenyl, which may be substituted by phenyl or phenoxy which in turn may be substituted with nitro, halogen or amine.
- salts of compounds of formula (I) can be prepared which can be considered physiologically acceptable. These include addition salts derived from inorganic or organic acids, for example, acetates, fumarates, glutarates, glutaconates, lactates, maleates, methanesulphonates, phosphates, salicylates, succinates, sulphates, sulphamates, tartrates and paratoluenesulphonates. In some cases, solvates of either the free nucleosides or the acid addition salts can be isolated and these solvates may, for example, be hydrates or alcoholates.
- the compounds of formula (I) have affinity for subtypes of adenosine receptors, modulate cyclic AMP and act as cytokine inhibitors. Moreover, these compounds are found to be useful as drugs in the treatment of disorders where damaging effects of cytokines are observed in humans.
- the compounds according to the invention possess desirable pharmacological properties which can be ascribed to cytokine modulation. For example they inhibit TNF- ⁇ synthesis, as indicated by lowering of plasma TNF- ⁇ following lipopolysaccharide (LPS) challenge in rats.
- LPS lipopolysaccharide
- HEK 293 cells were cultured in Dulbecco's modified Eagles media supplemented with 10% fetal bovine serum, 2 MM glutamine, 0 1 mg/mL streptomycin, 0 1 mg/mL penicillin and 0 8 mg/mL G418 in an incubator at 37°C (95% air, 5% CO 2 )
- HEK 293 cells were seeded in 24-well plates two days before the experiment so that they were 70-80% confluent on the day of the assay Cells were washed twice with 1 mL of assay buffer (the composition was 1 18 mM NaCl, 25 MM NaHCO 3 , 4 7 mM KCI, 1 2 mM KH 2 PO 4 , 1 2 mM CaCl 2 , 3 8 itiM MgCl 2 , 1 2 mM MgSO 4 , 1 1 mM D-glucose and 10 mM HEPES, pH 7 4) The cells were subsequently incubated for 15 min at
- Test compounds or buffer were added to the cells before [ 125 I]-AB- MECA and incubated for 45 min. at 37°C in a final volume of 500mL.
- the cells were washed quickly with 2 x 2 mL ice-cold assay buffer, solubilised with 1 mL of NaOH (2 M) and transferred to g-counting vials with 0.5 mL water.
- Test compounds are dissolved in DMSO, ethanol or water and further diluted in assay buffer. The final concentrations of solvents should be less than 2%. Test solutions should be in the range of pH 6.5 - 7.5. IC50 values were calculated from dose-response curves (3 points minimum) by a non-linear regression analysis using the GraphPad Prism program (GraphPad Software, USA). The results expressed in nM.
- test compound is dissolved in dimethyl sulphoxide (DMSO) at 8 mg/mL and is diluted with Cremophor in 5% saline (0.9% aqueous NaCl) to 160, 16 and 1.6 ⁇ g/mL. 25 ⁇ L is added to each tube, and 350 mL heparinised (50 iE/mL) rat blood, 25 ⁇ L lipopolysaccharide (LPS) 1.6 mg/mL in saline are introduced, i.e. the concentrations of the test compound is 10, 1 and 0.1 mg uL respectively.
- the samples are shaken carefully and are placed in a water bath for 5 h. at 37°C.
- the samples are centrifuged for 10 min. at 3000 ⁇ m at 4°C.
- the plasma is removed by pipette in plastic tubes and is frozen. TNF- ⁇ levels are determined using a Genzyme ELISA kit.
- the compounds of the invention together with a conventional adjuvant, carrier or diluent, and if desired in the form of a pharmaceutically acceptable acid addition salt thereof, may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets of filled capsules, or liquids, such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral use (including subcutaneous administration and infusion).
- Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the adenosine receptor agonist commensurate with the intended daily dosage range to be employed.
- Tablets containing ten (10) milligrams of active ingredient or, more broadly, ten (10) to hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
- the compounds of this invention can thus be used for the formulation of pharmaceutical preparation, e.g. for oral and parenteral administration to mammals including humans, in accordance with conventional methods of galenic pharmacy.
- excipients are such pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral or enteral application which do not deleteriously react with the active compounds.
- Such carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy- methylcellulose and polyvinylpyrrolidone.
- the pharmaceutical preparations can be sterilised and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds.
- injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
- Ampoules are convenient unit dosage forms.
- a syrup, elixir or the like can be used in cases where a sweetened vehicle can be employed.
- the compounds of this invention are dispensed in unit form comprising 0.05-100 mg in a pharmaceutically acceptable carrier per unit dosage.
- the dosage of the compounds according to this invention is 0.1-300 mg/day, preferably 10-100 mg/day, when administered to patients, e.g. humans, as a drug.
- a typical tablet which may be prepared by conventional tabletting techniques contains:
- the compounds of the invention are extremely useful in the treatment of related symptoms in mammals, when administered in an amount effective for agonist activity of compounds of the invention.
- the compounds of the invention may accordingly be administered to a subject, e.g., a living animal body, including a human, in need of adenosine receptor agonist, and if desired in the form of a pharmaceutically acceptable acid addition salt thereof (such as the hydrobromide, hydrochloride, or sulphate), in any event prepared in the usual or conventional manner, e.g., evaporation to dry- ness of the free base in solution together with the acid), ordinarily concurrently, simultaneously, or together with a pharmaceutically acceptable carrier or diluent, especially and preferably in the form of a pharmaceutical composition thereof, whether by oral, rectal, or parenteral (including subcutaneous) route, in an effective amount of adenosine receptor agonist, and in any event an amount which is effective for the treatment diseases related to cytokines, owing to their adenosine receptor agonist activity.
- a pharmaceutically acceptable acid addition salt thereof such as the hydrobromide, hydrochloride, or sulphate
- Suitable dosage ranges are 1-200 milligrams daily, 10-100 milligrams daily, and especially 30-70 milligrams daily, depending as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and the preference and experience of the physician or veterinarian in charge.
- TLC thin layer chromatography
- THF tetrahydrofuran
- TFA trifluoracetic acid
- m.p. melting point. Where melting points are given, these are uncorrected.
- the structures of the compounds are confirmed by assignment of NMR spectra (from which representative peaks are quoted) and by microanalysis where appropriate.
- Compounds used as starting materials are either known compounds or compounds which can be prepared by methods known per se. Column chromatography was carried out on Merck silica gel 60 (Art 9385).
- HPLC was carried out on a Waters or Merck chromatograph with a multiwavelength detector and a reversed phase C18 column (250 x 4 mm, 5mm, lOOA; eluent flow rate 1 mL/ min at 35°C). Retention times are given in minutes.
- Phenylacetaldehyde (24.0 g, 0.20 mol), a 33% solution of methylamine in ethanol (42.35 g, 0.41 mol) and methylamine hydrochloride (10.13 g, 14.8 mmol) were dissolved in methanol (200 mL).
- Sodium cyanoborohydride (3.77 g, 60 mmol) was introduced and the reaction mixture was stirred at room temperature for 18 h.
- the reaction mixture was evaporated in vacuo to ca. 50 mL, concentrated hydrochloric acid (40 mL) was added and once the exotherm had subsided the reaction mixture was stirred for 2 h.
- N-methyl-2-phenylethylamine hydrochloride (6.4 g, 37.3 mmol) was dissolved in water (18 mL), ethanol (11 mL) and 2 N hydrochloric acid ( 4 mL) were introduced and the solution was heated to 70°C.
- 2,6-dichloro-9H-purine (5.8 g, 30.7 mmol) and 1-O-acetyl-tri-O-benzoyl- ⁇ -D-ribofuranose (16.26 g, 32.2 mmol) were thoroughly mixed (as powdery solids) and fused together at 145-150°C under oil pump vacuum. The resultant oily mixture was stirred gently for 0.75 h (during which time the acetic acid by-product evaporated) and cooled to ca. 50°C before being dissolved in dichloromethane (100 mL) with stirring.
- This example was prepared by a method similar to that described in Example 1. 9-(2 , ,3 , ,5 , -Tri-O-benzoyl- ⁇ -D-ribofuranosyl)-2,6-dichloro-9H-purine (2.0 g, 3.2 mmol), O-(phenylmethyl)hydroxylamine hydrochloride (0.77 g, 4.8 mmol) and (1.03 g, 8.0 mmol) were dissolved in dioxan (50 mL). The reaction mixture was heated at reflux for 20h, filtered and evaporated in vacuo.
- the title compound was prepared by reacting O-[(4-nitrophenyl)methyl]hydroxylamine hydro ⁇ chloride (1.43 g, 7 mmol) with 6-chloropurine riboside (i.e. 9- ⁇ -D-ribofi ⁇ ranosyl-6-chloro-9H- purine) (1.0 g, 3.5 mmol) in DMF (40 mL) at 110°C for 2 h with diisopropylethylamine (1.80 g, 14 mmol) present.
- the reaction mixture was evaporated and to the resultant residue was added saturated sodium bicarbonate solution (20 mL) and water (20 mL). Methanol was gradually added until the residue dissolved, and the solid which gradually precipitated was removed by filtration.
- N-Hydroxyphthalimide (15.0 g, 92 mmol) and sodium acetate (7.5 g, 92 mmol) were stirred in dimethylsulfoxide (70 mL) at ambient temperature for 3h.
- 2-Chloroethylbenzene (12.5 g, 89 mmol) was added and the reaction mixture was heated at reflux for 2 h. After cooling and standing overnight the reaction mixture was filtered and the filtrate was poured onto ice/water (300 mL). The mixture was extracted with dichloromethane (4 x 100 mL), the combined extracts were dried (MgSO 4 ) and evaporated in vacuo to a residue.
- N-(2-Phenylethoxy)phthalimide (11.3 g, 42 mmol) was dissolved in hot 96% ethanol (100 mL). Hydrazine hydrate (2.5 g, 50 mmol) was introduced and the reaction mixture was heated at reflux with mechanical stirring for 1.5h. The reaction mixture was stored at 4°C for 72 h, filtered and the filtrate was evaporated in vacuo. The crude white residue was suspended in toluene and stored at 4°C for 16h and filtered. The filtrate was treated with a solution of chlorotrimethyl- silane (4.34 g) in toluene (200 mL) with methanol (1.05 g) present and the title compound precipitated.
- Ci8H 2 oClN 5 O 5 . 0.75 H 2 O requires C, 49.7; H, 5.0; N, 16.1. Found C, 49.9; H, 4.9; N, 15.8%.
- the title compound was prepared according to the method described in Example 6 by reacting O-cyclopentylhydroxylamine (prepared by the overall procedure described in example 5) (0.78 g, 5.67 mmol) with 9-(2',3',5'-tri-O-benzoyl- ⁇ -D-ribofi ⁇ ranosyl)-2,6-dichloro-9H-purine (3.0 g, 4.74 mmol), followed by debenzoylation of the purified product using methanolic ammonia to provide the title 2-chloro-N-cyclopentoxyadenosine (0.11 g) (after column chromatography) as a solid, mp 116-119°C.
- the title compound was prepared according to the method descnbed in Example 4 by reacting O-methylhydroxylamine (0 20 g, 2 0 mmol) with 9-(2',3',5'-tri-O-benzoyl- ⁇ -D-ribofuranosyI)- -2,6-dichloro-9H-purine (1 27 g, 20 mmol) and debenzoylating the purified product using methanolic ammonia to provide the title 2-chloro-N-methoxyadenosine (040 g, 45%) (after column chromatography) as a colorless foam which became crystalline on t ⁇ turation with dichloromethane, providing 020 g of a white solid, mp 123 - 125°C l H NMR (DMSO-de) d
- the title compound was prepared according the method described in example 6 by reacting O- ethylhydroxylamine hydrochloride (0305 g, 3 1 mmol) with 9-(2 , ,3 , ,5'-tri-O-acetyl- ⁇ -D-ribo- fi ⁇ ranosyl)-2,6-dichloro-9H-purine (1 79 g, 4 0 mmol), followed by deacylation of the purified product using sodium methoxide in methanol to provide the title 2-chloro-N-ethoxyadenosine (0 161 g, 21%) (after column chromatography) as a foam, l H NMR (DMSO-ds) d 1 25 (3H, t, - CH 2 CH3), 3.52 - 3 58 (Hi m, H-5'.), 3 63 - 3 70 (IH, m, H-5' b ), 3 94 (IH, q, H-4'), 4 00 (2H,
- the title compound was prepared according to the method descnbed in Example 6 by reacting O-(l-propyl)hydroxylam ⁇ ne hydrochloride with 9-(2 , ,3',5 l -t ⁇ -0-acetyl- ⁇ -D-ribofuranosyl)- -2,6-dichloro-9H-purine, followed by deacylation of the purified product using sodium methoxide in methanol to provide the title 2-chloro-N-(l-propyloxy)adenosine (after column chromatography) as a foam
- the title compound was prepared according to the method descnbed in Example 6 by reacting isobutoxyamine hydrochloride (0603 g, 4 8 mmol) with 9-(2',3',5'-tri-O-acetyl- ⁇ -D-ribo- furanosyl)-2,6-dichloro-9H-pu ⁇ ne (1 79 g, 4 0 mmol), followed by deacylation of the purified product using sodium methoxide m methanol to provide the title 2-chloro-N-ethoxyadenosine (0 31 g, 42%) (after column chromatography) as a foam, ⁇ NMR (DMSO-d*) d 0 96 (6H, 2t, - CH(CH 3 2 ), 20 (IH, h, -CH.C ⁇ CHa ⁇ ), 3 52 - 3 58 (Hi m, H-5' a ), 3 63 - 3 70 (IH, m, H-5' b ), 3
- the title compound was prepared according to the method described in Examples 4 and 5 by reacting 0-[l,2,3,4-tetrahydronaphth-l-yl)hydroxylamine (prepared by the procedure described in example 6) (0.35 g, 2.0 mmol) with 9-(2',3',5'-tri-O-benzoyl- ⁇ -D-ribofuranosyl)-2,6-dichloro- -9H-purine (1.0 g, 1.58 mmol) and debenzoylating the purified product using methanolic ammonia to provide the title 2-chloro-iV-(l,2,3,4-tetrahydronaphth-l-yloxy)adenosine (0.10 g, 15%) (after column chromatography) as a colorless foam (a mixture of diastereoisomers), *H NMR (DMS ⁇ -d «) d 1.65 - 2.85 (6H, m, -CH 2 CH 2 CH 2 -),
- the title compound was prepared by reacting 1 -methyl- l-(2-phenoxyethyl)hydrazine (prepared by the general method described in Example 1) (0.80 g, 4 mmol) and 9-(2,3,5-tri-O-benzoyl- ⁇ - D-ribofuranosyl)-2,6dichloro-9H-purine (2.53 g, 4 mmol) and triethylamine (1.11 mL, 8 mmol) in dioxan (25 mL), followed by debenzoylation of the purified product using methanolic ammonia to provide the title 2-cUoro-N-(N-methyl-/V-(2-phenoxyethyl)amino)adenosine (0.84 g, 47%) (after column chromatography) obtained as a solid, mp 166-8°C, *H NMR (DMSO-d*) d 2.70 (3ti s, -CH 3 ), 3.22 (2H, br t,
- O-Cyclopentylhydroxylamine hydrochloride (0.52 g, 3.75 mmol) was reacted with 9-(2',3',5'-tri- O-acetyl- ⁇ -D-ribofuranosyl)-6-chloro-2-methyl-9H-purine (1.07 g, 2.5 mmol) [prepared from 2-methylinosine (Journal of Organic Chemistry, 1967, 32, 3258 - 3260) by standard acylation and chlorination steps] in dioxan (40 mL) in the presence of triethylamine (0.63 g, 6.25 mmol).
- O-Methylhydroxylamine hydrochloride (0.20 g, 2.4 mmol) was reacted with 9-(2',3',5'-tri- O-acetyl- ⁇ -D-ribofuranosyl)-6-chloro-2-methyl-9H-purine (0.85 g, 2.0 mmol) (see Example 20) in dioxan (40 mL) in the presence of triethylamine (0.52 g, 5.0 mmol). The reaction mixture was heated at 90°C in a sealed vessel for 70h, before being filtered and evaporated.
- This compound was prepared by the method described in Example 24.
- 2-Chloro-N-(4-phenyl- thio-l-piperidinyl)adenosine [WO 93/08206 (Novo Nordisk A/S)] (0.5 g, 1 mmol) was subjected to the reaction conditions described above, providing the title 5'-deoxy-2,5'-dichloro-N-(3-phenyl- thio-l-piperidinyl)adenosine (mixture of diastereoisomers) as a foam (0.48 g, 94%) following flash chromatography on silica gel.
- reaction mixture was evaporated to a residue and purified by flash chromatography on silica gel, eluting with a mixture of dichloromethane and ethanol (9:1) to provide 5 , -deoxy-2,5'-dichloro-N-(4-phenylsulfinyl-l-piperidinyl)adenosine (0.1 g, 53%) as a foam.
- This compound was prepared by the method described in Example 24.
- 2-Chloro-N-- (dimethylamino)adenosine [WO 93/23417 (Novo Nordisk A/S)] (0.62 g, 1.8 mmol) was subjected to the chlorination conditions described above (Example 24), providing the title 5'- deoxy-2,5'-dicMoro-N-(dimethylamino)adenosine as a solid (0.23 g, 41%) after column chromatography, .p.
- N-Cyclo- pentoxy-2-chloroadenosine [WO 93/23417 ( ⁇ ovo Nordisk A S)] (1.0 g, 2.6 mmol) was subjected to the chlorination conditions described in Example 24, providing the title N-cyclopentoxy-5'-deoxy-2,5'-dichloroadenosine as a foam (0.82 g, 78%), 1H-NMR (400MHz, DMSO-d «) d 1.49 - 1.92 (8H, 3m, cyclopentyl C-H), 3.86, 3.94 (2H, ABX, H-5' a and H-5' b ), 4.11 (Hi q, H-4'), 4.20 (Hi q, H-3'), 4.59 (Hi m, -OC-H), 4.67 (IH, q, H-2'), 5.51, 5.64 (Hi 2d, 2'-and 3'-OH), 5.90 (IH
- Methyl 2,3-O-(l-methylethylidene)-5-O-(p-toluenesulfonyl)-D-ribofuranoside (28.7 g, 80 mmol) was dissolved in dry acetonitrile (100 mL). Tetra-w-butylammonium fluoride (100 mL, 1.0M in THF) was added dropwise and the reaction mixture was heated at 80°C for 72 h. After cooling to room temperature, the mixture was diluted with dichloromethane (200 mL), washed with water (3 x 50 mL) and dried (MgSO 4 ).
- Methyl 5-deoxy-5-fluoro-2,3-O-(l-methylethylidene)-D-ribofuranoside (5.0 g, 24 mmol) was treated with sulfuric acid (0.02M, 40 mL) and heated at reflux for 4 h. The reaction mixture was cooled, neutralized with barium carbonate to pH 7, filtered and evaporated to an oil. The oil was dried by coevaporation with ethanol, and the residue was dissolved in dichloromethane (50 mL). Acetic anhydride (25 mL) and pyridine (25 mL) were introduced, and the reaction mixture was stirred for 16 h before being poured onto ice (100 mL).
- This compound was prepared by general method A, described in more detail in Example 39 by reacting O-benzylhydroxylamine hydrochloride (0.80 g, 5.0 mmol) with 9-[(2',3'-di-O-acetyl-5'- deoxy-5'-fluoro-D-ribofuranosyl)]-2,6-dichloro-9H-purine (1.0 g, 2.5 mmol) as described above.
- Methyl 2,3-O-(l-methylethylidene)-D-ribofuranoside (13.3 g, 60 mmol), 2,6-di-t-butyl-4-methyl- pyridine (20.0 g, 100 mmol) and methyl trifluoromethylsulfonate (16.0 g, 100 mmol) were dis ⁇ solved in dry dichloromethane (150 mL) placed in a closed reactor and heated to 80°C. After cooling, the reaction mixture was poured onto ice (150 mL). After standing, the product was extracted into dichloromethane (2 x 100 mL) and the combined extracts were dried (MgS ⁇ ) and evaporated in vacuo.
- 5-O-Methyl-2,3-O-(l-methylethylidene)-D-ribofuranoside (3.0 g, 14 mmol) was dissolved in a mixture of sulfuric acid (0.02M, 100 mL) and ethanol (50 mL) and heated at 80°C for 6 h and stirred for 20 h at 20°C.
- the reaction mixture was neutralised with aqueous sodium bicarbonate and concentrated in vacuo.
- the residual oil was dried and acetylated in a mixture of dichloromethane (100 mL), acetic anhydride (8.5 g, 83 mmol) and triethylamine (16.7 g, 165 mmol) at 20°C for 20 h.
- reaction mixture was washed with hydrochloric acid (IM, 50 mL) and water (50 mL).
- IM hydrochloric acid
- organic phase was dried (MgSO ) and concentrated to an oil before being purified by flash chromatography. Elution with a mixture of cyclohexane and ethyl acetate (6:4) provided l,2,3-tri-O-acetyl-5-O-methyl- ⁇ -D-ribofuranose (2.5g, 62%) as an oil.
- the crude product was purified by flash chromatography eluting with a mbcture of dichloromethane and 10% ammonia in ethanol (95:5) to give 2-chloro-5'-deoxy-5'-methylthio-2',3'-O-( 1 -methylethylidene)-JV-( 1 -piperidinyl)adenosine (0.12 g, 31%) as a foam.
- Methyl 2,3-O-(l-methylethylidene)-5-O-(4-nitrobenzenesulfonyl)- ⁇ -D-ribofuranoside (45.3 g, 120 m mol) was added over 1.5 h to a suspension of sodium cyanide (6.8 g, 140 mmol) in dry dimethylformamide (1000 mL). The reaction mixture was heated to 50°C for 3 h before being poured onto ice (500 mL). This mixture was extracted with dichloromethane (3 x 500 mL), the combined extracts were dried (MgSO 4 ) and concentrated in vacuo.
- Ci ⁇ HzoClN- requires C, 48.8; H, 5.1; N, 24.9. Found C, 48.9; H 5.3; N, 24.6%.
- Methyl 5-deoxy-2,3-O-(l-methylethylidene)-D-ribofuranoside (prepared by reduction of methyl 2,3-O-(l-methyiethylidene)-5'-O-(p-toluenesulphonyl)-D-ribofuranoside using lithium aluminium hydride) (4.36 g, 23.2 mmol) was dissolved in methanol (120 mL) and Amberlyst resin (FT form, 19 g) was introduced. The mixture was stirred at 80°C for 60 h and filtered. The filter pad was washed with methanol and the filtrate was evaporated to an oily residue.
- Amberlyst resin FT form
- Triphenylmethylphosphonium bromide (26.79 g, 75 mmol) was suspended in THF (200 mL) and n-butyllithium (1.7M in hexanes) (42 mL, 71.2 mmol) was introduced.
- Methyl 5-deoxy-2,3-O-(l-methylethylidene)-5-methylene-D-ribofuranoside (5.65 g, 28.2 mmol) was dissolved in methanol (250 mL) and Amberlyst resin (Ff form, 30 g) was introduced. The mixture was stirred at ambient temperature for 40 h and was filtered. The filter pad was washed with methanol and the filtrate was evaporated to an oily residue.
- 2,3-Di-O-benzoyl-2-chloro-5'-deoxy-5'-methylene-N-cyclopentyladenosine prepared by reaction of 9-(5'-deoxy-2',3 , -di-O-benzoyl-5'-methylene- ⁇ -D-ribofuranosyl)-2,6-dichloro-9H-purine (see Example 48) with cyclopentylamine) (0.30 g, 0.52 mmol) was dissolved in methanolic ammonia (10 mL) and stirred at ambient temperature for 18 h.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU20225/97A AU2022597A (en) | 1996-03-13 | 1997-03-12 | A method of treating disorders related to cytokines in mammals |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK29396 | 1996-03-13 | ||
DK0293/96 | 1996-03-13 | ||
DK0591/96 | 1996-05-21 | ||
DK59196 | 1996-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997033591A1 true WO1997033591A1 (fr) | 1997-09-18 |
Family
ID=26063711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1997/000108 WO1997033591A1 (fr) | 1996-03-13 | 1997-03-12 | Procede de traitement d'affections associees aux cytokines chez les mammiferes |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2022597A (fr) |
WO (1) | WO1997033591A1 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024451A3 (fr) * | 1997-11-08 | 1999-08-19 | Glaxo Group Ltd | Composes chimiques |
WO1999024449A3 (fr) * | 1997-11-08 | 1999-08-19 | Glaxo Group Ltd | Composes chimiques |
WO1999024450A3 (fr) * | 1997-11-08 | 1999-08-19 | Glaxo Group Ltd | Composes chimiques |
US5998388A (en) * | 1996-05-14 | 1999-12-07 | Glaxo Wellcome Inc. | Adenosine derivatives |
WO2002070532A3 (fr) * | 2001-03-03 | 2002-11-28 | Univ Leiden | Nouveaux derives c2,5'disubstitues et n6',c2,5'-trisubstitues de l'adenosine et leurs differentes utilisations |
EP1375508A1 (fr) * | 2002-06-27 | 2004-01-02 | Aventis Pharma Deutschland GmbH | Dérivés de l'adénosine N6-substitués et leur utilisation comme médicament |
WO2004016635A3 (fr) * | 2002-08-15 | 2004-04-08 | Cv Therapeutics Inc | Agonistes partiels et totaux des recepteurs d'adenosine a1 |
WO2005033121A3 (fr) * | 2003-10-03 | 2005-07-28 | King Pharmaceuticals Res & Dev | Synthese de 2-aralkyloxyadenosines, 2-alkoxyadenosines, et leurs analogues |
US7265111B2 (en) | 2002-06-27 | 2007-09-04 | Sanofi-Aventis Deutschland Gmbh | Adenosine analogues and their use as pharmaceutical agents |
US7342003B2 (en) | 2001-10-25 | 2008-03-11 | King Pharmaceuticals Research And Development, Inc. | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988003147A1 (fr) * | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Adenosines a substitution n6 selectionees ayant une activite de liaison a2 selective |
EP0322242A2 (fr) * | 1987-12-23 | 1989-06-28 | Glaxo Group Limited | Dérivés d'adénosine |
EP0472181A2 (fr) * | 1990-08-22 | 1992-02-26 | Merrell Pharmaceuticals Inc. | 5-Amino analogues de l'adénosine comme agents immunosuppressants |
EP0490818A1 (fr) * | 1990-12-07 | 1992-06-17 | Sandoz Ltd. | Hydrate de 6-cyclohexyl-2'-0-methyl-adenosine et son utilisations |
WO1993008206A1 (fr) * | 1991-10-24 | 1993-04-29 | Novo Nordisk A/S | Nouveaux derives de purine 2,6-disubstitues |
WO1993023417A1 (fr) * | 1992-05-14 | 1993-11-25 | Novo Nordisk A/S | Nouveaux derives de l'adenosine |
WO1995003304A1 (fr) * | 1993-07-23 | 1995-02-02 | Merrell Pharmaceuticals Inc. | Nouveaux agents nucleosidiques 9-n-bicycliques utilises comme inhibiteurs selectifs des cytokines proinflammatoires |
WO1995007921A1 (fr) * | 1993-09-17 | 1995-03-23 | Novo Nordisk A/S | Composes chimiques, leur preparation et leur utilisation |
-
1997
- 1997-03-12 AU AU20225/97A patent/AU2022597A/en not_active Abandoned
- 1997-03-12 WO PCT/DK1997/000108 patent/WO1997033591A1/fr active Search and Examination
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988003147A1 (fr) * | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Adenosines a substitution n6 selectionees ayant une activite de liaison a2 selective |
EP0322242A2 (fr) * | 1987-12-23 | 1989-06-28 | Glaxo Group Limited | Dérivés d'adénosine |
EP0472181A2 (fr) * | 1990-08-22 | 1992-02-26 | Merrell Pharmaceuticals Inc. | 5-Amino analogues de l'adénosine comme agents immunosuppressants |
EP0490818A1 (fr) * | 1990-12-07 | 1992-06-17 | Sandoz Ltd. | Hydrate de 6-cyclohexyl-2'-0-methyl-adenosine et son utilisations |
WO1993008206A1 (fr) * | 1991-10-24 | 1993-04-29 | Novo Nordisk A/S | Nouveaux derives de purine 2,6-disubstitues |
WO1993023417A1 (fr) * | 1992-05-14 | 1993-11-25 | Novo Nordisk A/S | Nouveaux derives de l'adenosine |
WO1995003304A1 (fr) * | 1993-07-23 | 1995-02-02 | Merrell Pharmaceuticals Inc. | Nouveaux agents nucleosidiques 9-n-bicycliques utilises comme inhibiteurs selectifs des cytokines proinflammatoires |
WO1995007921A1 (fr) * | 1993-09-17 | 1995-03-23 | Novo Nordisk A/S | Composes chimiques, leur preparation et leur utilisation |
Non-Patent Citations (2)
Title |
---|
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, Volume 72, No. 10, 1994, FRED D. ROMANO et al., "The Antiadrenergic Effect of Cyclopentyladenosine on Myocardial Contractility is Reduced in Vivo in Diabetic Rats", page 1245. * |
MOLECULAR AND CELLULAR BIOCHEMISTRY, Volume 144, 1995, LESLEY HESELTINE et al., "Adenosine Effects Upon Insulin Action on Lipolysis and Glucose Transport in Human Adipocytes", pages 147-151. * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998388A (en) * | 1996-05-14 | 1999-12-07 | Glaxo Wellcome Inc. | Adenosine derivatives |
US6455510B1 (en) | 1997-11-08 | 2002-09-24 | Smithkline Beecham Corporation | Chemical Compounds |
WO1999024450A3 (fr) * | 1997-11-08 | 1999-08-19 | Glaxo Group Ltd | Composes chimiques |
WO1999024449A3 (fr) * | 1997-11-08 | 1999-08-19 | Glaxo Group Ltd | Composes chimiques |
JP2001522859A (ja) * | 1997-11-08 | 2001-11-20 | グラクソ グループ リミテッド | 化合物 |
US6407076B1 (en) | 1997-11-08 | 2002-06-18 | Smithkline Beecham Corporation | Adenosine analogues and related method of treatment |
US6544960B1 (en) | 1997-11-08 | 2003-04-08 | Smithkline Beecham Corporation | Chemical compounds |
WO1999024451A3 (fr) * | 1997-11-08 | 1999-08-19 | Glaxo Group Ltd | Composes chimiques |
US6740644B2 (en) | 1997-11-08 | 2004-05-25 | Smithkline Beecham Corporation | Chemical compounds |
EP1457495A1 (fr) * | 1997-11-08 | 2004-09-15 | Glaxo Group Limited | Agonistes des récepteurs d'adénosine A1 |
US7084127B2 (en) | 2001-03-03 | 2006-08-01 | Universiteit Leiden | C2,5′-disubstituted and N6, C2,5′-trisubstituted adenosine derivatives and their different uses |
WO2002070532A3 (fr) * | 2001-03-03 | 2002-11-28 | Univ Leiden | Nouveaux derives c2,5'disubstitues et n6',c2,5'-trisubstitues de l'adenosine et leurs differentes utilisations |
US7189706B2 (en) | 2001-03-03 | 2007-03-13 | Universiteit Leiden | C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them |
US7342003B2 (en) | 2001-10-25 | 2008-03-11 | King Pharmaceuticals Research And Development, Inc. | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs |
WO2004003002A1 (fr) * | 2002-06-27 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Nouveaux analogues de l'adenosine et leur utilisation comme agents pharmaceutiques |
US7265111B2 (en) | 2002-06-27 | 2007-09-04 | Sanofi-Aventis Deutschland Gmbh | Adenosine analogues and their use as pharmaceutical agents |
EP1375508A1 (fr) * | 2002-06-27 | 2004-01-02 | Aventis Pharma Deutschland GmbH | Dérivés de l'adénosine N6-substitués et leur utilisation comme médicament |
JP2006505525A (ja) * | 2002-08-15 | 2006-02-16 | シーブイ・セラピューティクス・インコーポレイテッド | A1アデノシン受容体の部分および完全アゴニスト |
US7022681B2 (en) | 2002-08-15 | 2006-04-04 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
WO2004016635A3 (fr) * | 2002-08-15 | 2004-04-08 | Cv Therapeutics Inc | Agonistes partiels et totaux des recepteurs d'adenosine a1 |
RU2340623C2 (ru) * | 2002-08-15 | 2008-12-10 | Си Ви Терапьютикс, Инк. | Частичные и полные агонисты аденозиновых рецепторов a1 |
WO2005033121A3 (fr) * | 2003-10-03 | 2005-07-28 | King Pharmaceuticals Res & Dev | Synthese de 2-aralkyloxyadenosines, 2-alkoxyadenosines, et leurs analogues |
Also Published As
Publication number | Publication date |
---|---|
AU2022597A (en) | 1997-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU784374C (en) | Synthesis of 2'-deoxy-L-nucleosides | |
US5589467A (en) | 2,5',N6-trisubstituted adenosine derivatives | |
KR101195019B1 (ko) | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 | |
EP1928475B1 (fr) | Dérivés anitivraux de phosphoramidates de pronucléotides 4'-c-azido-substitués | |
KR20030061792A (ko) | 뉴클레오시드 유도체 | |
SK287875B6 (sk) | Use of 4'-substituted nucleosides for the manufacture of a medicament for the treatment of diseases mediated by the Hepatitis C Virus | |
US7084127B2 (en) | C2,5′-disubstituted and N6, C2,5′-trisubstituted adenosine derivatives and their different uses | |
WO1998001459A1 (fr) | Nouveaux derives de n-alcoxyadenine inhibant la cytokine | |
IL103513A (en) | 2-N-disubstituted adenosine derivatives their preparation and pharmaceutical compositions containing them | |
WO1997033591A1 (fr) | Procede de traitement d'affections associees aux cytokines chez les mammiferes | |
WO1997033590A1 (fr) | Procede de traitement d'affections associees aux cytokines chez les mammiferes | |
WO1998016539A1 (fr) | Nouveaux derives d'adenosine a action therapeutique | |
Mulamoottil et al. | Recent Advances in Synthesis and Biological Activity of 4′‐Thionucleosides | |
EP1634888A2 (fr) | Synthèse de 2'-désoxy-L-nucléosides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97532210 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |